# Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

> **NCT07219238** · PHASE2,PHASE3 · RECRUITING · sponsor: **GE Healthcare** · enrollment: 175 (estimated)

## Conditions studied

- Colorectal Cancer
- Gastric Cancers
- Ovarian Cancers
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)

## Key facts

- **NCT ID:** NCT07219238
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-06
- **Final completion:** 2029-08
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07219238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07219238, "Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07219238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*